PPBT News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

PP

Mkt Cap

$1.9M

Volume

21.11K

Next Earnings

November 13th

Chart Earnings News About Insider Filings

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual CongressPurple Biotech will present new preclinical data on its CAPTN-3 platform of conditionally activated tri-specific antibodies at the ESMO Immuno-Oncology 2025 Congress, showcasing potential advances in cancer treatment targeting tumor immune evasion and drug resistance.GlobeNewswire Inc. · Dec 4, 2025

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price NotificationPurple Biotech received a Nasdaq letter indicating non-compliance with minimum bid price requirements, with 180 days to regain compliance by raising its stock price above $1.00 per share.GlobeNewswire Inc. · Oct 20, 2025

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsPurple Biotech closed a public offering raising $6 million upfront, with potential additional proceeds of $12 million through short-term warrant exercises. The company plans to use funds for oncology therapeutic candidate development and working capital.GlobeNewswire Inc. · Sep 5, 2025

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025Purple Biotech reported significant progress in its oncology pipeline, including promising Phase 2 results for CM24 in pancreatic cancer, advancements in the CAPTN-3 tri-specific antibody platform, and initiation of a Phase 2 study for NT219 in head and neck cancer.GlobeNewswire Inc. · Jul 23, 2025

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer TrialPurple Biotech is advancing its novel agent NT219 into a Phase 2 study in combination with pembrolizumab or cetuximab for the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study aims to address the significant unmet medical need in this patient population.GlobeNewswire Inc. · Feb 18, 2025

Purple Biotech Reports Third Quarter 2024 Financial ResultsPurple Biotech reported positive Phase 2 data for its CM24 pancreatic cancer treatment, including potential biomarkers that could improve outcomes in future studies. The company also provided updates on its NT219 and CAPTN-3 pipeline programs and financial results for Q3 2024.GlobeNewswire Inc. · Nov 15, 2024

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of DeathPurple Biotech has identified serum CEACAM1 as a potential new blood biomarker that may help determine which metastatic pancreatic ductal adenocarcinoma (PDAC) patients are most likely to benefit from treatment with its lead oncology therapeutic candidate CM24. Patients with serum CEACAM1 levels between 6K and 15K pg/mL demonstrated improved progression-free survival and overall survival when treated with CM24 in combination with other therapies.GlobeNewswire Inc. · Nov 4, 2024

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment ConferencePurple Biotech, a clinical-stage company developing therapies to overcome tumor immune evasion and drug resistance, will participate in the H.C. Wainwright 26th Annual Global Investment Conference with a virtual fireside chat and one-on-one meetings.GlobeNewswire Inc. · Aug 30, 2024

Purple Biotech Announces Exercise of Warrants for $2 Million Gross ProceedsREHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing 10 ordinary shares, having original exercise prices ranging from $1.25 to $20.00 per ADS, originally issued by Purple Biotech in October 2023, June 2020, January 2019 and June 2018, at a reduced exercise price of $0.36 per ADS. The issuance and/or resale of the ADSs issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form F-3 (File Nos. 333-268710, 333-235327 and 333-215037). The offering is expected to close on or about July 2, 2024, subject to satisfaction of customary closing conditions.GlobeNewswire Inc. · Jul 1, 2024

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit REHOVOT, Israel, June 27, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today reported additional positive interim data from its randomized, controlled, open label, multicenter Phase 2 study (NCT 04731467) of CM24, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard of care (SoC) chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma (PDAC). These results suggest that serum MPO may be a predictive biomarker for survival in the CM24+Nivolumab + Nal-IRI/5FU/LV arm. The company also announced that it will host a virtual KOL event on Thursday, July 11, 2024 at 10:30 AM ET to discuss the results in detail. To register for the event, click here.GlobeNewswire Inc. · Jun 27, 2024

PP

PPBTPurple Biotech Ltd. American Depositary Shares

PPBT

Pay with—

Available Balance0.00

Your PositionYou don't own any PPBT yet.

Related Tickers

Earnings